[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644514":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":19,"interventions":25,"overallOfficials":13,"centralContacts":33,"locations":13,"responsibleParty":39,"collaborators":13,"id":43,"slug":13,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":13,"eligibilityCriteria":48,"healthyVolunteers":44,"sex":49,"minAge":50,"maxAge":13,"enrollmentInfo":51,"targetDuration":13,"studyType":54,"phases":13,"briefSummary":55,"conditions":56,"keywords":13,"overallStatus":58,"whyStopped":13,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":13},{"fullName":5,"class":6},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Evaluate the correlation between the HER2 expression status of baseline CTCs\u002FCTECs and the overall response rate (ORR) of the entire population.","Evaluate the correlation between the HER2 expression status of baseline CTCs\u002FCTECs and the overall population's DCR, PFS, and OS. Evaluate the correlation between the baseline serum HER2 ECD level and the overall population's ORR, DCR, PFS, and OS.","through study completion, an average of 2 year",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"CASE_CONTROL","PROSPECTIVE","The study plans to include 100 patients and divide them into cohort A (HER2 low expression, 70 cases) and cohort B (HER2 IHC 0, 30 cases) based on the tissue HER2 status. This study adopts a non-random design, and patients will be directly included in the corresponding cohort according to their baseline tissue HER2 status. All enrolled patients will receive standard T-DXd treatment after signing the informed consent form until disease progression, occurrence of intolerable toxic reactions, or study termination. The primary endpoint of the study is to explore the correlation between the HER2 expression status of CTCs\u002FCTECs and ORR. The secondary endpoints include the correlation between the baseline HER2 expression status of CTCs\u002FCTECs and the DCR, PFS, and OS of the entire population; the correlation between the baseline serum HER2 ECD level and the ORR, DCR, PFS, and OS of the entire population; and the ORR and PFS of each cohort. Patients will be followed up from the first administration and samples of peripheral blood will be collected for biomarker dynamic monitoring before treatment, at 2 cycles of treatment, and at the time of disease progression (the number of tests may be increased or decreased according to the patient's condition) until disease progression, death, loss to follow-up, or study closure.","This study focused on breast cancer patients who had received treatment with anti-HER2-ADC drugs.",[20],{"label":21,"type":13,"description":22,"interventionNames":23},"Low expression of HER2","Patients with low HER2 expression (IHC 1+ or IHC 2+\u002FISH-) and HER2 IHC 0 advanced breast cancer",[24],"Drug: Anti-HER2-ADC drug Deruxtepracabine",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Anti-HER2-ADC drug Deruxtepracabine","By monitoring the levels of CTCs\u002FCTECs and serum HER2 expression in breast cancer patients receiving anti-HER2-ADC treatment during the treatment process, we aim to determine the therapeutic monitoring value of CTCs\u002FCTECs and serum HER2 in these breast cancer patients using anti-HER2-ADC drugs.",[21],[32],"Other medications: The doctor will determine the administration plan based on the specific circumstances.",[34],{"name":35,"role":36,"phone":37,"phoneExt":13,"email":38},"Yehui Shi Yehui Shi, Doctor of Medicine","CONTACT","+8618622221183","shiyehui@tjmuch.com",{"type":40,"investigatorFullName":41,"investigatorTitle":42,"investigatorAffiliation":5,"oldNameTitle":13,"oldOrganization":13},"PRINCIPAL_INVESTIGATOR","Yehui Shi","Chief Physician","100644514",false,"NCT07670182","The Efficacy of Combined Peripheral Blood CTCs and Serum HER2 Detection in Docetaxel-based Treatment for HER2 Low-expression Breast Cancer","A Prospective, Multicenter Clinical Study on the Efficacy Correlation of Deruxtepruzumab Treatment for Advanced Breast Cancer With Low\u002FUltra-low HER2 Expression, Guided by Peripheral Blood CTCs\u002FCTECs Combined With Serum HER2 Detection","Inclusion Criteria:\n\n1. Patients with a pathological record of breast cancer;\n2. Group A: Diagnosed with low expression of HER2 (IHC 1+ or IHC 2+ and ISH-); Group B: Diagnosed with HER2 0 expression (IHC 0);\n3. No history of other malignant tumors;\n4. Signed the informed consent form at the age of 18 or above;\n5. Possess relatively complete clinical case characteristic data.\n\nExclusion Criteria:\n\n* 1\\. Male breast cancer patients; 2. Pregnant or breastfeeding; 3. Patients known to have an allergic reaction to the active substances or any excipients of T-DXd; 4. Patients judged by the investigators to be unsuitable to participate in this study.","FEMALE","18 Years",{"count":52,"type":53},100,"ESTIMATED","OBSERVATIONAL","This study is a multicenter, double-cohort clinical research aimed at systematically evaluating the value of jointly detecting the HER2 expression of CTCs\u002FCTECs and the serum HER2 ECD level in predicting the efficacy of T-DXd treatment for patients with HER2 low expression (IHC 1+ or IHC 2+\u002FISH-) and HER2 IHC 0 advanced breast cancer.",[57],"Patients With Low HER2 Expression (IHC 1+ or IHC 2+\u002FISH-) and HER2 IHC 0 Advanced Breast Cancer","NOT_YET_RECRUITING","2026-06-24",{"date":61,"type":62},"2026-06-26","ACTUAL",{"date":64,"type":53},"2026-06-15",{"date":66,"type":53},"2031-01-01",{"name":5,"class":6}]